4 terminated, 2 completed. 5 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Terminated 3, Completed 2 |
| Phase 3 | 2 | Terminated 2 |
Follow Izokibep: new trials by email Literature Review of Izokibep trials Research Report on Izokibep
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Hidradenitis Suppurativa Study of Izokibep Placebo, Izokibep - Hidradenitis Suppurativa | Phase 3 | Terminated | ACELYRIN Inc. | 258 | 2023-06-22 | 2025-10-15 |
| Psoriatic Arthritis Study of Izokibep Izokibep, Placebo to izokibep - Psoriatic Arthritis | Phase 2 / Phase 3 | Terminated | ACELYRIN Inc. | 351 | 2022-11-21 | 2025-05-23 |
| Phase 2b Pivotal Study of Izokibep in Non-infectious, Intermediate-, Posterior- or Pan-uveitis Izokibep, Placebo - Uveitis | Phase 2 | Terminated | ACELYRIN Inc. | 96 | 2022-08-23 | 2025-02-21 |
| Hidradenitis Suppurativa Phase 2b Study of Izokibep Izokibep, Placebo to izokibep - Hidradenitis Suppurativa | Phase 2 | Completed | ACELYRIN Inc. | 205 | 2022-05-05 | 2025-06-03 |
| A Trial of the Efficacy and Safety of Izokibep in the Treatment of Non-anterior Uveitis Izokibep, Prednisone/Prednisolone - Uveitis | Phase 2 | Completed | ACELYRIN Inc. | 7 | 2022-01-06 | 2024-02-12 |
| ABY-035 in the Treatment of Subjects With Ankylosing Spondylitis ABY-035, Placebo - Ankylosing Spondylitis | Phase 2 | Terminated | Inmagene LLC | 25 | 2021-08-24 | 2023-07-12 |
Hidradenitis Suppurativa (2) · Uveitis (2) · Arthritis (1) · Arthritis, Psoriatic (1) · Psoriasis (1) · Spondylitis, Ankylosing (1) · Uveitis, Intermediate (1) · Uveitis, Posterior (1)
ACELYRIN Inc. (5) · Inmagene LLC (1)
United States (6) · Germany (4) · Spain (4) · Canada (3) · Hungary (3) · Poland (3) · Czechia (2) · France (2) · Austria (1) · Bulgaria (1) · China (1) · Italy (1) · Japan (1) · South Korea (1)
Donald Betah, MD (2) · Donald Betah (1) · Lawrence He (1) · Shepard Mpofu, MD, Clinical Development (1) · Shephard Mpofu (1)